Expanding our global reach.


StageBio expands its capabilities on both sides of the Atlantic with the acquisition of TPL Path Labs.

TPL Path Labs of Freiburg, Germany is now part of StageBio. This important development expands our solution portfolio and enhances our ability to satisfy the preclinical and clinical histopathology and molecular pathology needs of our clients worldwide.


Your international research partner

With this acquisition, StageBio now offers:

  • A GLP/GCLP-compliant lab facility in Germany, in addition to our 6 GLP lab facilities and 2 GLP specimen archive sites in the U.S.
  • 175+ professionals, including 30 experienced pathologists and more than 75 laboratory technicians
  • A broad array of solutions across the preclinical, translational, and clinical continuum—from study protocol development through necropsy, histology, pathology, image analysis and archiving
  • Enhanced ability to support investigators in a broad range of fields, including:
    • Tissue cross-reactivity (TCR) studies
    • Molecular pathology
    • Immunohistochemistry (IHC) and Immunofluorescence (IF)
    • In situ hybridization (ISH) and Fluorescence in situ hybridization (FISH)
    • Biomarker development
    • Digital imaging and image analysis
    • Specialty histology techniques

Expanded benefits for you

One trusted source for all your preclinical and clinical histopathology / molecular pathology needs, in markets around the world

Uniform technology platforms and protocols across all operations, ensuring consistent quality, accuracy and efficiency

Reduced need to ship study materials overseas for preparation and analysis; especially samples from clinical studies

A responsive team of life science experts committed to exceptionally responsive service—whether you are a global biopharmaceutical company, a CRO or an early-stage startup

Ready to get started? 

Request a consultation.


StageBio: Your international research partner

Histopathology  •  Molecular Pathology  •  Image Analysis  •  Archival Services

Learn more about StageBio’s COVID-19 response